Micafungin Hikma Farmacêutica (Portugal) (Micafungin)

Micafungin inhibits the enzyme β‑(1,3)‑D‑glucan synthase, which is required for the synthesis of β‑(1,3)‑D‑glucan, an essential component of the fungal cell wall. By blocking this pathway, the drug weakens the cell wall, leading to osmotic instability and fungal cell lysis while sparing human cells that lack this target.

The specific dose and duration of Micafungin therapy are determined by the prescribing healthcare professional based on the patient’s condition, severity of infection, renal and hepatic function, and other clinical factors. Dosage regimens are not standardized in public documents and should follow the prescriber’s order.

Safety data for Micafungin during pregnancy and lactation are limited. The medication should only be used if the potential benefit justifies the potential risk to the fetus or infant. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss risks and alternatives with their healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide. After submission, the sales team will verify trade or institutional credentials, then provide pricing, availability, shipping details (including cold‑chain logistics if needed), and required import documentation.

The primary alternative class for systemic Candida infections is the azole antifungals (e.g., fluconazole, voriconazole). Compared with azoles, Micafungin offers a different mechanism of action, is less affected by azole‑resistance mechanisms, and has a lower potential for drug‑drug interactions mediated by CYP enzymes. However, azoles are available in oral formulations, while Micafungin requires intravenous administration.

Micafungin intravenous solution should be stored at 2‑8 °C (refrigerated). It must be kept in its original container, protected from light, and should never be frozen or shaken. Prior to administration, the solution may be allowed to reach room temperature, but any unused portion should be discarded according to local regulations.

Micafungin is given as an intravenous infusion. The infusion is typically administered over a period of 30 to 60 minutes, depending on the prescribed dose and clinical protocol. Administration should be performed by qualified healthcare personnel in a setting equipped to monitor for infusion‑related reactions.

Serious adverse events associated with Micafungin include hepatic failure, severe allergic reactions such as anaphylaxis, renal impairment, and rare skin reactions like Stevens‑Johnson syndrome. Patients should be monitored for signs of liver dysfunction, sudden rash, breathing difficulty, or decreased urine output, and any concerning symptoms should prompt immediate medical evaluation.

Micafungin is contraindicated in individuals with a known hypersensitivity to Micafungin or any component of the formulation. Caution is also advised for patients with severe hepatic impairment, as the drug is primarily metabolized by the liver. Clinicians should evaluate the risk‑benefit profile before prescribing to patients with significant liver disease or a history of severe allergic reactions.